Slide 1: First Quarter Fiscal Year 2012 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) First Quarter of Fiscal Year 2012 (1QFY12) Conference Call and Webinar January 18, 2012
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to su
Slide 3: Continuing and Discontinued Operations
With the sale of our former Words+ subsidiary on November 30, 2011, we will now be reporting financials and comparing reporting periods for only the continuing operations, composed almost entirely of the pharmaceutical software and services business (Abbreviate!™ and FutureLab ™ contribute very litt
Slide 4: SLP 1Q12 Highlights
SLP 1Q12 Highlights Three months ended 11/30/2011 • 1Q12 compared to 1Q11 (pro forma): – 17 th consecutive profitable quarter (39 of last 41 were profitable) – 1Q12 sales increased 9.6% to $2.248 million from $2.050 million – This represents another record first quarter – Net income increased 30.9%
Slide 5: Income Statement 1QFY12 vs 1QFY11
Income Statement 1QFY12 vs 1QFY11 ($ millions) 1Q12 1Q11 (pro forma) Net sales 2.248 2.050 Gross profit 1.896 1.697 Gross profit margin 84.3% 82.8% SG&A 0.700 0.686 R&D 0.252 0.201 Total operating expenses 0.952 0.887 Income from operations 0.944 0.810 Other income 0.120 0.024 Income before income t
Slide 6: Pro Forma Income Statement Year Ended 8/31/2011
Pro Forma Income Statement Year Ended 8/31/2011 ($ millions) unaudited SLP Consolidated as reported Words+, Inc. as reported in consolidated Pro Forma adjustment (a) SLP Pro Forma as adjusted Net sales 11.720 2.981 (2.981) 8.739 Gross profit 8.841 1.600 (1.600) 7.241 Gross profit margin 75.4% 53.7%
Slide 7: Revenues by Fiscal Year
$3.2 $5.7 $6.1 $6.3 $7.6 $8.7 $2.2 2006 2007 2008 2009 2010 2011 2012 $ Millions 2006 2007 2008 2009 2010 2011 2012 Q1 only Revenues by Fiscal Year (pro forma prior to 2012)
Slide 8: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.6 $2.0 $1.1 $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $0 $1 $2 $3 Q1 Q2 Q3 Q4 2008 2009 2010 2011 2012 $2.2
Slide 9: Net Income by Fiscal Year
Net Income by Fiscal Year (pro forma prior to 2012)
Slide 10: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012)
Slide 11: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) November 30, 2011 November 30 , 2010 Cash and cash equivalents $12.662 $8.873 Cash per share 0.785 0.537 Total current assets 13.275 11.775 Total assets 14.586 14.063 Total current liabilities 1.100 1.095 Total liabilities 1.872 1.581 Current ratio 13.3 10.8
Slide 12: Marketing and Sales Program
Marketing and Sales Program • Conferences/Scientific Meetings – primary source of leads – we do 50 - 60/year, adding shows in China • Posters, Presentations, and Peer - Reviewed Publications • Training Workshops – now adding Basic GastroPlus training to ongoing Advanced GastroPlus training courses •
Slide 13: Ongoing Enhancements
• Simulations Plus continues to increase its technological advantage Ongoing Enhancements • Version 8.0 release scheduled for February 2012 – major upgrade • Expanded drug - drug interaction to include transporters and induction • Expanded PDPlus™ pharmacodynamics modeling module • Expanded ocular d
Slide 14: FDA Food Safety Research Collaboration
FDA Food Safety Research Collaboration • We entered into a 5 - year renewable Research Collaboration with the Center for Food Safety and Applied Nutrition (CFSAN) to provide model - building capabilities for a large number (>10,000) of substances that can be in foods as additives or contaminants. •
Slide 15: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • When drug companies invent (“discover”) a new molecule, it is called a new chemical entity (NCE) • The process of getting to an approvable drug molecule usually involves making and test a large number of molecules to find good “lead candidates”. Lead candidates ar
Slide 16: Summary
Summary • For 1QFY11: - All financial performance measure are up nicely and strong growth trend for revenues and income continues - Sale of Words+ has simplified and focused the business – margins jump about 10%, reporting and auditing much simpler going forward • Continuing to Expand our Life Scien
Slide 17: simulationsplus, ine, ¢
simulationsplus, ine, ¢